易瑞生物(300942) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 reached ¥294,001,215.63, representing a 100.11% increase compared to ¥146,917,926.77 in the same period last year[4] - Net profit attributable to shareholders was ¥114,128,972.49, a 30.27% increase from ¥87,610,355.16 year-over-year[4] - Basic and diluted earnings per share increased by 21.74% to ¥0.28 from ¥0.23[4] - The net profit after deducting non-recurring gains and losses was RMB 108 million, up 36.32% year-on-year[15] - The company’s total operating revenue reached CNY 294,001,215.63 for the current period, a significant increase from CNY 146,917,926.77 in the previous period, representing a growth of approximately 100%[21] - The net profit for Q1 2022 was CNY 114,098,297.86, an increase of 30.3% compared to CNY 87,599,429.10 in Q1 2021[22] - The total comprehensive income for Q1 2022 was CNY 114,017,886.19, compared to CNY 86,965,485.64 in the same period last year[22] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥51,177,229.38, a decline of 152.13% compared to ¥98,176,735.85 in the previous year[4] - The company's cash and cash equivalents decreased to CNY 306,951,385.94 from CNY 342,211,180.47 at the beginning of the year, a decline of approximately 10.2%[17] - The cash flow from operating activities showed a net outflow of CNY -51,177,229.38, compared to a net inflow of CNY 98,176,735.85 in the same period last year[24] - The company reported cash and cash equivalents at the end of Q1 2022 amounting to CNY 303,982,289.69, down from CNY 464,332,177.81 at the end of Q1 2021[26] - The company generated CNY 437,566,466.36 in cash inflow from investment activities, significantly higher than CNY 206,207,905.11 in the previous year[24] - The net cash flow from investment activities was CNY 15,956,035.85, recovering from a net outflow of CNY -190,871,815.39 in Q1 2021[26] Assets and Liabilities - Total assets grew by 16.17% to ¥1,338,832,695.50 from ¥1,152,520,292.55 at the end of the previous year[4] - The total liabilities increased to CNY 264,902,209.87 from CNY 205,940,193.12, representing a rise of approximately 28.6%[19] - The company's retained earnings rose to CNY 466,114,874.37 from CNY 351,985,901.88, an increase of about 32.4%[20] - Accounts receivable increased significantly to CNY 201,003,768.99 from CNY 97,051,672.70, reflecting a growth of about 106.5%[17] - The inventory level rose to CNY 119,298,357.46 from CNY 93,859,305.88, marking an increase of approximately 27.1%[18] Research and Development - Research and development expenses increased by 45.98% to ¥15,605,979.98 as the company focused on industry trends[8] - The company continues to increase R&D investment to enhance product development and intellectual property protection[15] - The company added 7 new authorized patents during the reporting period, including 3 domestic invention patents and 2 overseas patents[15] Business Expansion and Partnerships - The company expanded its POCT business sales channels through a partnership with Hong Kong Xiangda Biological[15] - The company established a wholly-owned subsidiary, Aido Biology, to enhance product innovation and accelerate the acquisition of new veterinary drug certifications[16] - The company has partnered with professional investment institutions to establish Zhengrui Investment, aimed at enhancing the overall competitiveness and expanding the industrial chain[16] Market and Regulatory Environment - The demand for COVID-19 testing products remains strong due to the ongoing impact of the Omicron variant[15] - The company is committed to monitoring the pandemic situation to contribute to domestic and international epidemic prevention efforts[15] - The company obtained domestic medical device registration for its COVID-19 antigen test kit in March 2022[15] Operating Costs - The gross profit margin was impacted by a 311.55% increase in operating costs, which reached ¥96,408,256.89[8] - The total operating costs for the current period were CNY 155,220,845.49, compared to CNY 57,064,106.14 in the previous period, indicating an increase of about 172%[21] Shareholder Information - The company’s major shareholder, Shenzhen Yirui Holdings, holds 37.67% of the shares, with 151 million shares pledged[10]